Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years

Hepatology

Volumn 53, Issue 4, 2011, Pages 1148-1153

  Fung, James ^a   Lai, Ching Lung ^a   Yuen, John ^a   Cheng, Charles ^a   Wu, Ringo ^a   Ka Ho Wong, Danny ^a   Seto, Wai Kay ^a   Hung, Ivan Fan Ngai ^a   Yuen, Man Fung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; DNA DETERMINATION; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION TEST; MALE; MUTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79953759250     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24192     Document Type: Article

References (20)

1. Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
2. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
3. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai V, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007: 1295-1303.
4. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001; 34: 785-791.
5. Locarnini S, Qi S, Arterburn S, Snow A, Brosgart C, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42: 17.
6. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536.
7. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. HEPATOLOGY 2007; 64: 1695-1703.
8. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
9. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
10. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: A88-89.
11. Niro GA, Fontana R, Gioffreda D, Fiorella S, Accadia L, Iacobellis A, et al. Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study. Dig Liver Dis 2007; 39: 857-863.
12. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 2006; 58: 1031-1035.
13. Lee JM, Kim HJ, Park JY, Lee CK, Kim do Y, Kim JK, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009; 14: 705-712.
14. Leemans WF, Janssen HL, Niesters HG, de Man RA. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat 2008; 15: 108-114.
15. Seo YS, Kim JH, Yeon JE, Park JJ, Kim JS, Byun KS, et al. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol 2007; 13: 4072-4079.
16. Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007; 12: 41-46.
17. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 Lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451.
18. Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, et al. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009; 44: 864-870.
19. Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther 2006; 11: 779-786.
20. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049.